Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Private Placement Announcement: Titan Pharmaceuticals completed a private placement of 60,000 shares of Series C Convertible Preferred Stock to Blue Harbour Asset Management for $600,000, with a conversion price set at $3.40 per share.
Ownership Limitations and Agreements: The agreement includes a provision limiting Blue Harbour's ownership of common stock to avoid exceeding 19.99% without shareholder approval, and it also establishes registration rights for future needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
